The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin-Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 3, 2013, Pages 198-202

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GAMMA INTERFERON; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISORDERS OF CARBOHYDRATE METABOLISM; EVENING DOSAGE; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LYMPHOCYTE; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; LYMPHOCYTES; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84873731450     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12003     Document Type: Article

References (19)

1. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;2:9-15.
2. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007;186:461-5.
3. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E etal. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008;31(Suppl 2):S155-60.
4. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010;33:2266-70.
5. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011;107:1010-8.
6. Krysiak R, Okopien B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis 2010;213:325-8.
7. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M etal. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004;176:327-35.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
9. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. Curr Opin Lipidol 2008;19:469-77.
10. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7(Suppl 1):328-31.
11. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
12. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006;4:205-13.
13. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P etal. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
14. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP etal. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
15. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ etal. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604.
16. Keating GM, Omrod D. Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002;62:1909-44.
17. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJ etal. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
18. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004;110 (Suppl):S834.
19. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75.